BioStem Technologies Requests Extension to File 2024 Annual Report with OTC Markets Group

Biostem Technologies Announces Extension to File 2024 Annual Report with OTC

April 25, 2025 - Miami, FL - Biostem Technologies, Inc. (OTC: BSTE), a biotechnology company focused on developing innovative solutions for the treatment of various diseases, announced today that it has been granted an extension to file its 2024 annual report with the OTC Markets Group.

The company has been working diligently to complete its annual report, which is due to be filed with the OTC Markets Group by April 30, 2025. However, due to unforeseen circumstances, the company requires additional time to complete the filing.

"We are pleased to announce that we have been granted an extension to file our 2024 annual report," said Dr. Jorge Fernandes, CEO of Biostem Technologies. "We are committed to providing our shareholders with timely and accurate information about our company's progress and financial performance. We are working closely with our auditors and other stakeholders to complete the filing as soon as possible."

The extension will allow Biostem Technologies to complete its annual report, which will provide an update on the company's financial performance and business operations for the year ended December 31, 2024. The company expects to file the annual report by May 15, 2025.

Biostem Technologies is a biotechnology company focused on developing innovative solutions for the treatment of various diseases. The company is currently working on several projects, including the development of a novel gene therapy for the treatment of inherited retinal diseases.

For more information about Biostem Technologies, please visit the company's website at www.biostemtech.com.